Abstract
Overview
Introduction
The treatment of Rheumatoid Arthritis (RA) has been rapidly evolving over the
last decade. The success of the next wave of novel RA therapies depends on
their ability to address the key issue of cost effectiveness, as the patient
population for anti-TNF' s is reaching a maximum and competition moves to
anti-TNF failure patients.
Scope
- Detailed pipeline analysis for key products in a specific RA indication,
plus drug sales forecasts to 2016.
- Overview of patient potential, segmentation by indication and unmet needs
in RA across the seven major markets
- Benchmarking of key clinical and company attractiveness of the late-Phase
pipeline products
- Detailed up to data clinical trial information
Report Highlights
The anti-TNF failure segment will be an area of increased competition over the
next five years, as new products avoid direct confrontation with the
established anti-TNF' s. This population will increase as more patients use
biologics and cycle through the anti-TNF' s, but there are a finite number of
eligible patients, especially if prices remain high.
The race is on between the Roche/Genentech/Biogen Idec and the Genmab/GSK
partnerships to launch a CD20-inhibiting monoclonal antibody to follow, and
build upon, the success shown by Rituxan/MabThera (rituximab) in the RA
indication. At present Roche with ocrelizumab have a slight, but uncertain,
advantage.
The majority (58%) of projects in human clinical trials are in Phase II
development showing the positive growth potential in the RA disease area.
However, a large proportion are small molecule, orally available products,
which have in the past shown a high attrition rate in Phase II.
Reasons to Purchase
- Understand why pricing restraint is necessary for the continued
exponential uptake and commercial growth of the biologic DMARDs
- Quantify the size and potential of the market for novel treatments in the
RA indication.
- Use analysis of the common molecular targets under investigation to find
gaps in the market for your product
| 
View Cart
